Approved for MARGENZA is indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease [see Dosage and Administration (2.1) and Clinical Studies (14.1) ].. Margetuximab-cmkb binds to the extracellular domain of the human epidermal…
Loading full data from Know Your Drugs Institute…